Market capitalization | $883.14m |
Enterprise Value | $286.40m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 8.69 |
P/S ratio (TTM) P/S ratio | 26.79 |
P/B ratio (TTM) P/B ratio | 0.82 |
Revenue growth (TTM) Revenue growth | -34.59% |
Revenue (TTM) Revenue | $32.96m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
9 Analysts have issued a AbCellera Biologics Inc forecast:
9 Analysts have issued a AbCellera Biologics Inc forecast:
Sep '24 |
+/-
%
|
||
Revenue | 33 33 |
35%
35%
|
|
Gross Profit | -59 -59 |
-
|
|
EBITDA | -216 -216 |
27%
27%
|
EBIT (Operating Income) EBIT | -308 -308 |
49%
49%
|
Net Profit | -176 -176 |
36%
36%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. It offers antibody discovery platform that searches, decodes and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease. The company was founded by Carl Lars G. Hensen, Kathleen Lisaingo, Kevin Heyries, Véronique Lecault and Daniel Da Costa on November 8, 2012 and is headquartered in Vancouver, Canada.
Head office | Canada |
CEO | Carl Hansen |
Employees | 586 |
Founded | 2012 |
Website | www.abcellera.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.